Abstract
Hip resurfacing, like other orthopaedic procedures, depends for its success upon the confluence of three factors: a well-designed device, implanted using good technique, in a properly selected patient.
Cleveland Clinic has had good mid-term results in more than 2,200 patients using the Birmingham device since its FDA approval in 2006. These results are quite similar to other reported series from many centers around the world.
All surgery was performed using an anterolateral approach. Males accounted for 72% of the patients, and the average age was 53 years (12‐84). More than 90% of the patients had a diagnosis of osteoarthritis, and femoroacetabular impingement was the predominant pathology. The average component head size in males was 51mm, and in females 45mm.
Complications were few, with no dislocations, no femoral loosening, one socket loosening, one head collapse, 2 femoral neck fractures, and 2 deep infections. There were two patients with metallosis, one due to component malposition, and one in a small, dysplastic female. There were no destructive pseudotumors.
Overall survivorship at up to 8 years was more than 99%. Survivorship in young males, under age 50 with OA was 100%.
New mushroom templates for head size are described. Additional imaging recommendations including a standing lateral of the pelvis, and a CT scan for femoral anteversion may be helpful in patient selection.
